July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Comparing Teleretinal Screening-Identified Diabetic Retinopathy with Diabetic Nephropathy and Other Markers of Systemic Disease
Author Affiliations & Notes
  • Sean Michael Rodriguez
    School of Medicine, Baylor College of Medicine, Houston, Texas, United States
  • Eric B. Hamill
    Department of Ophthalmology, Baylor College of Medicine-Cullen Eye Institute, Houston, Texas, United States
    Department of Ophthalmology, Ben Taub General Hospital-Harris Health System, Houston, Texas, United States
  • Nabeel Moon
    School of Medicine, Baylor College of Medicine, Houston, Texas, United States
  • Amritha Kanakamedala
    School of Medicine, Baylor College of Medicine, Houston, Texas, United States
  • Christina Y. Weng
    Department of Ophthalmology, Baylor College of Medicine-Cullen Eye Institute, Houston, Texas, United States
    Department of Ophthalmology, Ben Taub General Hospital-Harris Health System, Houston, Texas, United States
  • Footnotes
    Commercial Relationships   Sean Rodriguez, None; Eric Hamill, None; Nabeel Moon, None; Amritha Kanakamedala, None; Christina Weng, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1044. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sean Michael Rodriguez, Eric B. Hamill, Nabeel Moon, Amritha Kanakamedala, Christina Y. Weng; Comparing Teleretinal Screening-Identified Diabetic Retinopathy with Diabetic Nephropathy and Other Markers of Systemic Disease. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1044.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare the ophthalmic results of a diabetic retinopathy teleretinal (TRI) screening program in a large, urban, ethnic minority-predominant population with underlying systemic markers of disease.

Methods : Retrospective cohort analysis evaluating patients screened through the Harris Health System (HHS, Houston, TX) TRI program June 2013-December 2014. Patients’ teleretinal images were cross-referenced with the electronic medical record from HHS hospitals and clinics. Demographics, systemic comorbidities, and underlying markers of disease were collected for all patients. Student’s t-test was used for statistical analysis.

Results : 903 patients met inclusion criteria, of which 58.5% were Hispanic, 21.8% Black, 11.0 % Asian, and 8.1% Caucasian. The prevalence of any diabetic retinopathy (DR) was 28.3% and any diabetic nephropathy (DN) was 37.5%. For patients with any DR, mean hemoglobin A1c (HbA1c) was 9.2%; median values for BUN (blood urea nitrogen), Cr (creatinine), microalbuminuria, and SBP (systolic blood pressure) were 16.0, 0.8, 40.5, and 134, respectively. For patients with any DN, mean HbA1c was 8.9%; median values for BUN, Cr, BMI (body mass index), and SBP were 15.0, 0.8, 30.7, and 135, respectively. HbA1c, BUN, Cr, BUN/Cr, microalbuminuria, BMI, and SBP were significantly greater in patients with any degree of retinopathy compared with those without retinopathy (p < 0.05). HbA1c, BUN, Cr, TG (triglyceride), SBP, and DBP (diastolic blood pressure) were significantly greater in patients with any degree of DN compared to those without (p < 0.05). No statistically significant differences in TG, HDL (high-density lipoprotein), or LDL (low-density lipoprotein) were observed between patients with DR vs. no DR; no statistically significant differences in HDL and LDL were observed between those with DN vs. no DN.

Conclusions : Results of this community-based TRI screening study confirms a similar distribution of DR and DN prevalence to that shown in other studies that are based on in-clinic examinations of similar populations. Higher levels of HbA1c, BUN, Cr, and blood pressure appear to be associated with higher degrees of both DR and DN; therefore, patients with abnormal levels of these measures may carry a worse ophthalmic or nephropathic prognosis and benefit from more vigilant surveillance.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×